NAMina Bio is a human-relevant translational intelligence platform. We integrate 3D bioprinting, organoids, microphysiological systems, and AI-powered analytics to build predictive human disease platforms across the preclinical development lifecycle. ​We accelerate translational decision-making, reduce reliance on low-predictive animal models, and de-risk early-stage therapeutic development. Aligned with the FDA Modernization Act 2.0 and NIH New Approach Methodologies (NAMs), our mission is to support the transition toward more ethical, data-driven, and clinically relevant preclinical systems.